Publication date: February 15, 2026. A regulatory and clinical analysis reports on a completed trial assessing the efficacy factors of a 595 nm Pulsed Dye Laser for rosacea. The study examined two pulse duration settings, 6 ms and 10 ms, as device parameters and their association with treatment outcomes. The trial was conducted at The First Affiliated Hospital with Nanjing Medical University and is registered on ClinicalTrials.gov as NCT07410533. The sponsorship and completion status indicate ongoing attention to device parameter optimization in rosacea management.
What changed in the landscape for rosacea devices?
The notice describes a completed evaluation of a 595 nm Pulsed Dye Laser used for rosacea. It signals a shift toward examining how device settings affect outcomes rather than presenting final efficacy results. While the source does not disclose numbers, the emphasis on pulse duration points to regulatory interest in defining a safe and effective parameter envelope for this class of devices. In this context regulators may look for clear intent and performance criteria in any future submissions related to pulsed dye lasers.
What exactly was tested in the trial?
The trial tested two pulse duration settings for the 595 nm Pulsed Dye Laser. The same wavelength was applied to participants with rosacea, and the only variable was pulse duration describing the device performance. The trial is linked to The First Affiliated Hospital with Nanjing Medical University as sponsor, and ClinicalTrials.gov records NCT07410533 confirm the study has completed. The focus remains on deriving parameter related insights about safety and efficacy.
What are the regulatory implications of this trial?
From a regulatory point of view, this trial touches on how specific parameter choices influence device performance in a vascular focused laser. If future data show a link between pulse duration and outcomes, labeling and risk management documentation could reflect parameter specific guidance. Any results would require independent validation and publication to support regulatory submissions under MDR guidance. This analysis underscores the need for precise intended use and clear performance claims for device families that include the 595 nm dye laser.
What about safety and performance in this context?
Safety and performance considerations hinge on the disclosed trial design. The source does not provide final results, so readers should await publication to confirm whether the two settings meet accepted safety margins and produce meaningful clinical benefit. In clinical practice, practitioners assess vascular response and potential pigment change, scarring risk, and patient selection when using vascular lasers for rosacea. Regulators will review heat generation, exposure duration and cumulative effects as part of a comprehensive risk assessment.
Who sponsored the study and what is its status?
The sponsor listed is The First Affiliated Hospital with Nanjing Medical University. The ClinicalTrials.gov record shows the study as Completed, indicating that the planned endpoints were reached. The completion status supports ongoing interest in parameter based optimization and may lead to future data disclosure through publication or regulatory submissions. Sponsor transparency and data quality will shape how regulators assess the credibility of any results.
Frequently asked questions
- What was the focus of the trial described in the article? The trial focused on two pulse duration settings for a 595 nm Pulsed Dye Laser used to treat rosacea.
- Did the source provide efficacy results? The source did not disclose results; it emphasized that data would be needed to assess the impact of pulse duration on outcomes.
- Where can I find more information? The ClinicalTrials.gov record NCT07410533 is the primary public source for trial details.
Conclusion and practical takeaways
This regulatory style analysis highlights how parameter optimization matters for laser devices used in rosacea. While final data are not yet published in the provided text, the focus on pulse duration suggests that regulators and manufacturers will continue to monitor device settings as part of safety and performance evaluation. Clinicians should stay alert to future data releases and consider how parameter selection may affect treatment decisions and patient safety.
Disclaimer for professionals
This content is for informational purposes only and is not legal advice. It reflects informational material based on a source description and does not provide regulatory conclusions.
Where to learn more
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07410533?term=medical+device
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07410533?term=medical+device